2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. FOXO

FOXO

Forkhead box O

Forkhead Box O (FOXO) is a subfamily within the forkhead box transcription factor family, characterized by having a highly conserved DNA-binding domain (FOX). FOXO family in mammals mainly consists of four members, namely FOXO1, FOXO3, FOXO4, and FOXO6. FOXO is involved in regulating key cellular processes such as apoptosis, cell cycle progression, and resistance to oxidative stress, and it is primarily regulated by Akt-mediated phosphorylation. FOXO family is closely related to diseases. It often acts as a tumor suppressor in tumors, can trigger insulin resistance and pancreatic islet β-cell dysfunction in diabetes, and is also involved in the occurrence and development of some neurodegenerative diseases. In addition, it also has the activities of resisting stress and extending lifespan[1].

FOXO Isoform Specific Products:

FOXO Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-137038
    N-alpha-Tosyl-Lys chloromethyl ketone hydrochloride
    		Inhibitor
    N-alpha-Tosyl-Lys chloromethyl ketone hydrochloride (TLCK hydrochloride) is a Serine protease inhibitor with an IC50 of 12.0 μM against Caspase-3, 54.5 μM against Caspase-6, and 19.3 μM against Caspase-7. It inhibits thrombin-induced nuclear translocation of FOXO1. N-alpha-Tosyl-Lys chloromethyl ketone hydrochloride can be used in research related to leukemia and cardiovascular diseases.
    N-alpha-Tosyl-Lys chloromethyl ketone hydrochloride
  • HY-W013803
    Xanthosine dihydrate
    		Activator
    Xanthosine dihydrate is a nucleoside derived from xanthine and ribose. Xanthosine dihydrate activates the AMPK/FoxO1/AKT/GSK3β signaling cascade. Xanthosine dihydrate promotes cell proliferation and regulates blood glucose metabolism. Xanthosine dihydrate increases milk production in cows and goats. Xanthosine dihydrate is used in mammary stem cell and type 2 diabetes research.
    Xanthosine dihydrate
  • HY-176902
    NSC126188
    		Inhibitor
    NSC126188 is a RhoB inducer. NSC126188 can induce apoptosis by inhibiting Akt/FoxO3 signaling. NSC126188 can be used for the research of cancer, such as prostate cancer.
    NSC126188
  • HY-P5762A
    Phoenixin-14 TFA
    		Inhibitor
    Phoenixin-14 (PNX-14) TFA is an endogenous neuropeptide with multiple biological activities, and serves as the endogenous ligand of GPR173. Phoenixin-14 TFA reduces ROS production by inhibiting the HMGB1/TLR4/MyD88/NF-κB signaling axis, thereby exerting antioxidant and mitochondrial protective effects. Phoenixin-14 TFA inhibits FOXO3 phosphorylation by upregulating SIRT3 expression, suppresses apoptosis, and improves myocardial systolic/diastolic function. Phoenixin-14 TFA resists ferroptosis by activating the ATF4/SLC7A11/GPX4 axis; it activates ERK1/2 phosphorylation via GPR173. Phoenixin-14 TFA can be used in researches on neuroprotection, diabetes, cardiomyopathy, reproductive protection and so on.
    Phoenixin-14 TFA
  • HY-16461
    Solenopsin
    		Inhibitor
    Solenopsin ((-)-Solenopsin A) is an ATP-competitive and selective Akt-1 inhibitor with an IC50 of 5-10 μM, and also acts as an RSK1 inhibitor. Solenopsin inhibits the activities of PDK1 in lipid rafts, downregulates PI3K, blocks PI3K-dependent generation of 3-phosphoinositides, and suppresses the phosphorylation of FOXO1a. Solenopsin induces Mitophagy and ROS production, reduces mitochondrial oxygen consumption, and exhibits antiproliferative and antiangiogenic activities. Solenopsin can be used in research related to hyperproliferative skin diseases and malignant diseases.
    Solenopsin
  • HY-163982
    FOXJ1 agonist 1
    FOXJ1 agonist 1 (compound 16c) is an orally effective small molecule that can effectively enhance the expression of FOXJ1. Foxj1-IN-1 acts on the mammalian airway system composed of multiciliated cells (MCC) to prevent the development and onset of chronic obstructive pulmonary disease (COPD). Foxj1-IN-1 can induce the production of motile cilia in the respiratory system of zebrafish and mammals, and inhibit elastase-induced COPD mouse models. Foxj1-IN-1 has good liver microsomal stability, in vivo PK curve and AUC; it has no significant inhibition of CYP and hERG, and does not have significant cytotoxicity.
    FOXJ1 agonist 1
  • HY-N3021R
    D-chiro-Inositol (Standard)
    		Inhibitor
    D-chiro-Inositol is a stereoisomer of inositol that exhibits activities such as improving glucose metabolism, anti-tumor effects, anti-inflammatory properties, and antioxidant activity. D-chiro-Inositol effectively alleviates cholestasis by enhancing bile acid secretion and reducing oxidative stress. D-chiro-Inositol improves insulin resistance, lowers hyperglycemia and circulating insulin levels, reduces serum androgen levels, and ameliorates some metabolic abnormalities associated with X syndrome by mimicking the action of insulin. Additionally, D-chiro-Inositol can induce a reduction in pro-inflammatory factors (such as Nf-κB) and cytokines (such as TNF-α), thereby exerting anti-inflammatory effects. D-chiro-Inositol may be used in the study of liver cirrhosis, breast cancer, type 2 diabetes, and polycystic ovary syndrome.
    D-chiro-Inositol (Standard)
  • HY-101035R
    LOM612 (Standard)
    LOM612 (Standard) is the analytical standard of LOM612 (HY-101035). This product is intended for research and analytical applications. LOM612 is a potent FOXO relocator, with an EC50 value of 1.5 μM in U2fox RELOC cells.
    LOM612 (Standard)
  • HY-103100R
    SB-699551 (Standard)
    		Inhibitor
    SB-699551 (Standard) is the analytical standard of SB-699551 (HY-103100). This product is intended for research and analytical applications. SB-699551 is a potent and selective 5-HT5A antagonist with a Ki value of 5.1 μM. SB-699551 increases the phosphorylation levels of CREB and ATF1, and decreases the phosphorylation levels of AKT, PRAS40, P70S6K, FOXO1, and S6RP. SB-699551 improves drug-induced cognitive deficits. SB-699551 improves social withdrawal and forgetfulness. SB-699551 inhibits breast cancer.
    SB-699551 (Standard)
  • HY-107566A
    Conessine dihydrobromide
    		Inhibitor
    Conessine dihydrobromide is an orally active and BBB-penetrable selective histamine H3 receptor antagonist. The pKi values of Conessine dihydrobromide for rat and human H3 receptors are 7.61 and 8.27, respectively. Conessine dihydrobromide is an inhibitor of the multidrug efflux pump system in Pseudomonas aeruginosa and can enhance the activity of antibiotics. Conessine dihydrobromide has antimalarial activity. Conessine dihydrobromide can also be used in the research of muscle atrophy.
    Conessine dihydrobromide
FOXO Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.